ALGS
Aligos Therapeutics, Inc.
Price Chart
Latest Quote
$4.91
-0.43 (-8.05%)
Current Price
| Previous Close | $5.34 |
| Open | $5.30 |
| Day High | $5.34 |
| Day Low | $4.82 |
| Volume | 127,709 |
Stock Information
| Shares Outstanding | 5.39M |
| Total Debt | $4.35M |
| Cash Equivalents | $54.91M |
| Revenue | $4.71M |
| Net Income | $-90.32M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $30.38M |
| EPS (TTM) | $-9.78 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $-20.17M |
| Sales | $4.71M |
| Income | $-90.32M |
| Book/sh | $5.14 |
| Cash/sh | $10.19 |
| Employees | 82 |
Financial Ratios
| Quick Ratio | 2.35 |
| Current Ratio | 2.56 |
| Debt/Eq | 13.69 |
Returns & Margins
| ROA | -55.56% |
| ROE | -121.86% |
| Operating Margin | -951.55% |
Ownership
| Insider Ownership | 10.37% |
| Institutional Ownership | 55.08% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -1.23 |
| P/S | 6.46 |
| P/B | 0.96 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $56.29 |
Technical Indicators
| SMA20 | $5.73 |
| SMA50 | $6.50 |
| SMA200 | $8.30 |
| RSI | 35.40 |
| ATR | 0.4118 |
| Shares Float | 3.64M |
| Short Float | 10.19% |
| Short Ratio | 1.22 |
| Rel Volume | 0.89 |
Performance History
| Week | -13.86% |
| Month | -22.92% |
| Quarter | -29.66% |
| 6 Months | -50.25% |
| YTD | -46.22% |
| Year | -21.94% |
| 3 Years | -82.62% |
| 5 Years | -99.30% |
| 10 Years | -98.68% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-05 | $4.91 | 128,000 |
| 2026-06-04 | $5.34 | 169,100 |
| 2026-06-03 | $5.14 | 51,200 |
| 2026-06-02 | $5.25 | 175,700 |
| 2026-06-01 | $5.35 | 192,800 |
| 2026-05-29 | $5.70 | 105,700 |
| 2026-05-28 | $5.79 | 195,700 |
| 2026-05-27 | $5.60 | 92,900 |
| 2026-05-26 | $5.74 | 78,600 |
| 2026-05-22 | $5.76 | 136,200 |
| 2026-05-21 | $5.71 | 85,600 |
| 2026-05-20 | $5.60 | 132,600 |
| 2026-05-19 | $5.18 | 111,300 |
| 2026-05-18 | $5.36 | 167,300 |
| 2026-05-15 | $5.71 | 179,300 |
| 2026-05-14 | $6.69 | 214,100 |
| 2026-05-13 | $6.67 | 120,600 |
| 2026-05-12 | $6.47 | 95,000 |
| 2026-05-11 | $6.21 | 136,100 |
| 2026-05-08 | $6.44 | 318,600 |
| 2026-05-07 | $6.03 | 94,700 |
| 2026-05-06 | $6.37 | 151,000 |
About Aligos Therapeutics, Inc.
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-Ã agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifoscorvir sodium, a capsid assembly modulator, which is in Phase 2 B clinical trial; and ALG-097558, a small molecule ritonavir-free pan-coronavirus protease inhibitor which has completed a Phase 1 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Emory University; and Katholieke Universiteit Leuven. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
đ° Latest News
Aligos and Xiamen Amoytop sign deal for HBV therapy
Pharmaceutical Technology âĸ 2026-04-17T10:54:34Z
Here's Why Aligos Therapeutics (NASDAQ:ALGS) Must Use Its Cash Wisely
Simply Wall St. âĸ 2026-01-07T14:35:56Z
Does Aligos Therapeutics (ALGS) Have the Potential to Rally 737.74% as Wall Street Analysts Expect?
Zacks âĸ 2025-09-08T21:04:15Z
Sanofi Gets FDA Nod for Wayrilz in Immune Thrombocytopenia
Zacks âĸ 2025-09-01T16:30:00Z
RCKT Stock Rises as FDA Lifts Clinical Hold on Danon Disease Study
Zacks âĸ 2025-08-21T15:13:00Z
Wall Street Analysts Predict a 983.24% Upside in Aligos Therapeutics (ALGS): Here's What You Should Know
Zacks âĸ 2025-08-19T13:55:02Z
Allogene's Q2 Loss Narrower Than Expected, Pipeline in Focus
Zacks âĸ 2025-08-14T15:11:00Z
Aligos commences dosing in Phase II trial for chronic hepatitis B treatment
Clinical Trials Arena âĸ 2025-08-14T09:51:38Z
Aligos Therapeutics Second Quarter 2025 Earnings: Beats Expectations
Simply Wall St. âĸ 2025-08-09T12:29:11Z
Aligos Therapeutics, Inc. (ALGS) Reports Q2 Loss, Misses Revenue Estimates
Zacks âĸ 2025-08-06T22:00:02Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $2,186,000 | $3,945,000 | $15,529,000 | $13,907,000 |
| Operating Revenue | $2,186,000 | $3,945,000 | $15,529,000 | $13,907,000 |
| Expenses | ||||
| Total Expenses | $90,171,000 | $93,099,000 | $103,656,000 | $111,487,000 |
| Other Income Expense | $60,184,000 | $-46,132,000 | $-2,169,000 | - |
| Net Non Operating Interest Income Expense | $3,922,000 | $4,406,000 | $3,412,000 | $1,640,000 |
| Total Other Finance Cost | $-3,922,000 | $-4,406,000 | $-3,412,000 | - |
| Operating Expense | $90,171,000 | $93,099,000 | $103,656,000 | $111,487,000 |
| General And Administrative Expense | $20,718,000 | $22,830,000 | $30,616,000 | $26,410,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-24,193,000 | $-131,211,000 | $-87,679,000 | $-96,046,000 |
| Net Interest Income | $3,922,000 | $4,406,000 | $3,412,000 | $1,640,000 |
| Normalized Income | $-71,738,360 | $-94,766,720 | $-85,965,490 | $-96,046,000 |
| Net Income From Continuing And Discontinued Operation | $-24,193,000 | $-131,211,000 | $-87,679,000 | $-96,046,000 |
| Total Operating Income As Reported | $-87,985,000 | $-89,154,000 | $-88,127,000 | $-97,580,000 |
| Average Dilution Earnings | $0 | $0 | - | - |
| Net Income Common Stockholders | $-24,193,000 | $-131,211,000 | $-87,679,000 | $-96,046,000 |
| Net Income | $-24,193,000 | $-131,211,000 | $-87,679,000 | $-96,046,000 |
| Net Income Including Noncontrolling Interests | $-24,193,000 | $-131,211,000 | $-87,679,000 | $-96,046,000 |
| Net Income Continuous Operations | $-24,193,000 | $-131,211,000 | $-87,679,000 | $-96,046,000 |
| Pretax Income | $-23,879,000 | $-130,880,000 | $-86,884,000 | $-95,940,000 |
| Operating Income | $-87,985,000 | $-89,154,000 | $-88,127,000 | $-97,580,000 |
| Interest Income | - | - | $1,243,000 | $1,640,000 |
| Interest Income Non Operating | - | - | $1,243,000 | $1,640,000 |
| Per Share | ||||
| Diluted EPS | - | $-20.94 | $-34.20 | $-56.25 |
| Basic EPS | - | $-20.94 | $-34.20 | $-56.25 |
| Other | ||||
| Tax Effect Of Unusual Items | $12,638,640 | $-9,687,720 | $-455,490 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-145,364,000 | $-40,400,000 | $-82,889,000 | $-93,905,000 |
| Total Unusual Items | $60,184,000 | $-46,132,000 | $-2,169,000 | - |
| Total Unusual Items Excluding Goodwill | $60,184,000 | $-46,132,000 | $-2,169,000 | - |
| Reconciled Depreciation | $2,805,000 | $2,622,000 | $3,069,000 | $3,675,000 |
| EBITDA (Bullshit earnings) | $-85,180,000 | $-86,532,000 | $-85,058,000 | $-93,905,000 |
| EBIT | $-87,985,000 | $-89,154,000 | $-88,127,000 | $-97,580,000 |
| Diluted NI Availto Com Stockholders | $-24,193,000 | $-131,211,000 | $-87,679,000 | $-96,046,000 |
| Tax Provision | $314,000 | $331,000 | $795,000 | $106,000 |
| Gain On Sale Of Security | $60,184,000 | $-46,132,000 | $-2,169,000 | - |
| Research And Development | $69,453,000 | $70,269,000 | $73,040,000 | $85,077,000 |
| Selling General And Administration | $20,718,000 | $22,830,000 | $30,616,000 | $26,410,000 |
| Other Gand A | $20,718,000 | $22,830,000 | $30,616,000 | $26,410,000 |
| Diluted Average Shares | - | $6,264,612 | $2,563,470 | $1,707,809 |
| Basic Average Shares | - | $6,264,612 | $2,563,470 | $1,707,809 |
Fetched: 2026-05-30
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $53,545,000 | $-28,973,000 | $92,080,000 | $103,900,000 |
| Total Assets | $88,533,000 | $70,094,000 | $151,527,000 | $146,693,000 |
| Total Non Current Assets | $5,671,000 | $7,953,000 | $10,443,000 | $13,148,000 |
| Other Non Current Assets | $715,000 | $627,000 | $625,000 | $634,000 |
| Current Assets | $82,862,000 | $62,141,000 | $141,084,000 | $133,545,000 |
| Other Current Assets | $4,908,000 | $5,092,000 | $5,310,000 | $7,603,000 |
| Restricted Cash | $110,000 | $110,000 | $70,000 | $115,000 |
| Cash Cash Equivalents And Short Term Investments | $77,844,000 | $56,939,000 | $135,704,000 | $125,827,000 |
| Cash And Cash Equivalents | $18,303,000 | $36,997,000 | $135,704,000 | $81,347,000 |
| Cash Equivalents | $18,303,000 | $36,997,000 | $135,704,000 | $81,347,000 |
| Investmentin Financial Assets | - | - | - | $0 |
| Debt | ||||
| Total Debt | $5,250,000 | $8,375,000 | $11,138,000 | $12,574,000 |
| Long Term Debt And Capital Lease Obligation | $1,525,000 | $4,917,000 | $7,899,000 | $9,431,000 |
| Current Debt And Capital Lease Obligation | $3,725,000 | $3,458,000 | $3,239,000 | $3,143,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $34,988,000 | $99,067,000 | $59,447,000 | $42,793,000 |
| Total Non Current Liabilities Net Minority Interest | $13,755,000 | $77,330,000 | $35,541,000 | $9,664,000 |
| Other Non Current Liabilities | $47,000 | $46,000 | $46,000 | - |
| Derivative Product Liabilities | $12,183,000 | $72,367,000 | $27,596,000 | $0 |
| Current Liabilities | $21,233,000 | $21,737,000 | $23,906,000 | $33,129,000 |
| Current Deferred Liabilities | $0 | $151,000 | $1,308,000 | $9,210,000 |
| Payables And Accrued Expenses | $10,044,000 | $11,741,000 | $12,686,000 | $14,413,000 |
| Payables | $3,982,000 | $2,571,000 | $3,028,000 | $12,940,000 |
| Accounts Payable | $3,982,000 | $2,571,000 | $2,517,000 | $4,737,000 |
| Other Payable | - | $1,471,000 | $511,000 | $8,203,000 |
| Non Current Deferred Liabilities | - | - | $0 | $233,000 |
| Other Current Liabilities | - | - | - | $66,000 |
| Equity | ||||
| Common Stock Equity | $53,545,000 | $-28,973,000 | $92,080,000 | $103,900,000 |
| Total Equity Gross Minority Interest | $53,545,000 | $-28,973,000 | $92,080,000 | $103,900,000 |
| Stockholders Equity | $53,545,000 | $-28,973,000 | $92,080,000 | $103,900,000 |
| Gains Losses Not Affecting Retained Earnings | $468,000 | $451,000 | $545,000 | $401,000 |
| Other Equity Adjustments | $468,000 | $451,000 | $545,000 | $401,000 |
| Retained Earnings | $-642,201,000 | $-618,008,000 | $-486,797,000 | $-399,118,000 |
| Other | ||||
| Ordinary Shares Number | $6,178,230 | $3,864,436 | $3,003,876 | $1,716,919 |
| Share Issued | $6,178,230 | $3,864,436 | $3,003,876 | $1,716,919 |
| Tangible Book Value | $53,545,000 | $-28,973,000 | $92,080,000 | $103,900,000 |
| Invested Capital | $53,545,000 | $-28,973,000 | $92,080,000 | $103,900,000 |
| Working Capital | $61,629,000 | $40,404,000 | $117,178,000 | $100,416,000 |
| Capital Lease Obligations | $5,250,000 | $8,375,000 | $11,138,000 | $12,574,000 |
| Total Capitalization | $53,545,000 | $-28,973,000 | $92,080,000 | $103,900,000 |
| Additional Paid In Capital | $695,269,000 | $588,576,000 | $578,325,000 | $502,613,000 |
| Capital Stock | $9,000 | $8,000 | $7,000 | $4,000 |
| Common Stock | $9,000 | $8,000 | $7,000 | $4,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $1,525,000 | $4,917,000 | $7,899,000 | $9,431,000 |
| Current Deferred Revenue | $0 | $151,000 | $1,308,000 | $9,210,000 |
| Current Capital Lease Obligation | $3,725,000 | $3,458,000 | $3,239,000 | $3,143,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $7,464,000 | $6,387,000 | $6,673,000 | $6,297,000 |
| Current Accrued Expenses | $6,062,000 | $9,170,000 | $9,658,000 | $1,473,000 |
| Net PPE | $4,956,000 | $7,326,000 | $9,818,000 | $12,514,000 |
| Accumulated Depreciation | $-12,712,000 | $-11,782,000 | $-10,755,000 | $-9,568,000 |
| Gross PPE | $17,668,000 | $19,108,000 | $20,573,000 | $22,082,000 |
| Leases | $6,264,000 | $6,101,000 | $6,101,000 | $6,087,000 |
| Construction In Progress | $0 | $4,000 | $4,000 | $22,000 |
| Other Properties | $9,298,000 | $10,939,000 | $12,389,000 | $13,877,000 |
| Machinery Furniture Equipment | $2,106,000 | $2,064,000 | $2,079,000 | $2,096,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $59,541,000 | $19,942,000 | $0 | $44,480,000 |
| Non Current Deferred Revenue | - | - | $0 | $233,000 |
| Investments And Advances | - | - | - | $0 |
| Available For Sale Securities | - | - | - | - |
Fetched: 2026-05-30
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-82,940,000 | $-80,873,000 | $-79,016,000 | $-80,332,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-82,503,000 | $-80,743,000 | $-78,997,000 | $-79,389,000 |
| Cash Flow From Continuing Operating Activities | $-82,503,000 | $-80,743,000 | $-78,997,000 | $-79,389,000 |
| Operating Gains Losses | $-60,184,000 | $46,132,000 | $2,186,000 | - |
| Investing Activities | ||||
| Capital Expenditure | $-437,000 | $-130,000 | $-19,000 | $-943,000 |
| Investing Cash Flow | $-37,826,000 | $-18,279,000 | $44,981,000 | $-26,293,000 |
| Cash Flow From Continuing Investing Activities | $-37,826,000 | $-18,279,000 | $44,981,000 | $-26,293,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $101,345,000 | $0 | $17,443,000 | $0 |
| Financing Cash Flow | $101,635,000 | $355,000 | $88,328,000 | $164,000 |
| Cash Flow From Continuing Financing Activities | $101,635,000 | $355,000 | $88,328,000 | $164,000 |
| Net Common Stock Issuance | $101,345,000 | $0 | $17,443,000 | $0 |
| Common Stock Issuance | $101,345,000 | $0 | $17,443,000 | $0 |
| Net Other Financing Charges | - | - | - | - |
| Net Preferred Stock Issuance | - | - | - | - |
| Preferred Stock Issuance | - | - | - | - |
| Other | ||||
| Repayment Of Debt | $-14,000 | $-83,000 | $-96,000 | $-61,000 |
| End Cash Position | $18,413,000 | $37,107,000 | $135,774,000 | $81,462,000 |
| Beginning Cash Position | $37,107,000 | $135,774,000 | $81,462,000 | $186,980,000 |
| Changes In Cash | $-18,694,000 | $-98,667,000 | $54,312,000 | $-105,518,000 |
| Proceeds From Stock Option Exercised | $304,000 | $438,000 | $70,981,000 | $225,000 |
| Net Issuance Payments Of Debt | $-14,000 | $-83,000 | $-96,000 | $-61,000 |
| Net Long Term Debt Issuance | $-14,000 | $-83,000 | $-96,000 | $-61,000 |
| Long Term Debt Payments | $-14,000 | $-83,000 | $-96,000 | $-61,000 |
| Net Investment Purchase And Sale | $-37,389,000 | $-18,149,000 | $45,000,000 | $-25,350,000 |
| Sale Of Investment | $127,500,000 | $90,000,000 | $45,011,000 | $78,915,000 |
| Purchase Of Investment | $-164,889,000 | $-108,149,000 | $-11,000 | $-104,265,000 |
| Net PPE Purchase And Sale | $-437,000 | $-130,000 | $-19,000 | $-943,000 |
| Purchase Of PPE | $-437,000 | $-130,000 | $-19,000 | $-943,000 |
| Change In Working Capital | $-3,787,000 | $-4,955,000 | $-9,525,000 | $-1,552,000 |
| Change In Other Working Capital | $-151,000 | $-1,157,000 | $-8,135,000 | $2,502,000 |
| Change In Other Current Liabilities | $-3,112,000 | $-2,680,000 | $-2,386,000 | $-1,952,000 |
| Change In Other Current Assets | $96,000 | $216,000 | $2,297,000 | $5,316,000 |
| Change In Payables And Accrued Expense | $-620,000 | $-1,334,000 | $-1,301,000 | $-7,418,000 |
| Change In Accrued Expense | $-2,031,000 | $-1,388,000 | $918,000 | $-9,140,000 |
| Change In Payable | $1,411,000 | $54,000 | $-2,219,000 | $1,722,000 |
| Change In Account Payable | $1,411,000 | $54,000 | $-2,219,000 | $1,722,000 |
| Stock Based Compensation | $5,044,000 | $8,452,000 | $12,652,000 | $14,693,000 |
| Amortization Of Securities | $-2,188,000 | $-1,783,000 | $-424,000 | $-159,000 |
| Depreciation Amortization Depletion | $2,805,000 | $2,622,000 | $3,069,000 | $3,675,000 |
| Depreciation And Amortization | $2,805,000 | $2,622,000 | $3,069,000 | $3,675,000 |
| Depreciation | $2,805,000 | $2,622,000 | $3,069,000 | $3,675,000 |
| Gain Loss On Investment Securities | $-60,184,000 | $46,132,000 | $2,169,000 | - |
| Net Income From Continuing Operations | $-24,193,000 | $-131,211,000 | $-87,679,000 | $-96,046,000 |
| Asset Impairment Charge | - | $0 | $724,000 | $0 |
| Interest Paid Supplemental Data | - | - | - | $0 |
| Income Tax Paid Supplemental Data | - | - | - | $0 |
Fetched: 2026-05-30